Corcept Therapeutics Incorporated CORT reported first-quarter 2020 earnings of 25 cents per share, surpassing the Zacks Consensus Estimate of 21 cents and also improving from the year ago quarter’s 15 cents.
Taking into account the impact of stock-based compensation and utilization of deferred tax assets, adjusted earnings came in at 34 cents per share compared with 20 cents in the year-ago quarter.
Revenues in the reported quarter surged 44% from the prior-year period to $93.2 million, primarily backed by higher sales and the strong uptake of Corcept’s Cushing’s syndrome drug, Korlym. Sales also beat the Zacks Consensus Estimate of $87 million.
Research and development expenses increased 29.2% to $26.1 million. Selling, general and administrative expenses also escalated 13.1% to $27.5 million.
Shares of Corcept have inched up 4.9% so far this year against the industry’s decrease of 13%.
Corcept reiterated its 2020 revenue guidance. The company expects total revenues in the range of $355-375 million.
Corcept’s lead candidate relacorilant is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. Dosing is currently underway in the above-mentioned study at sites across the United States, Israel and Europe. The company plans to submit a new drug application for relacorilant in the second quarter of 2022.
Corcept plans to start a phase III study, GRADIENT, on relacorilant in the second quarter of 2020 in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Meanwhile, Corcept’s phase II study on relacorilant plus Celgene's [now part of Bristol Myers BMY] Abraxane (nab-paclitaxel) to treat metastatic ovarian cancer is actively enrolling patients at sites in the United States and Europe, and is on track to produce results in first-half 2021.
Corcept plans to start the phase III study of relacorilant plus Abraxane to treat patients with metastatic pancreatic cancer in second-quarter 2020.
The company also expects to begin a phase Ib study on relacorilant plus Merck’s MRK PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), to treat patients with metastatic or unresectable adrenal cancer in the third quarter of 2020.
Corcept Therapeutics Incorporated Price, Consensus and EPS Surprise
Corcept Therapeutics Incorporated price-consensus-eps-surprise-chart | Corcept Therapeutics Incorporated Quote
Zacks Rank and Another Key Pick
Corcept currently sports a Zacks Rank #1 (Strong Buy). Another top-ranked stock in the same sector is Avenue Therapeutics, Inc. ATXI, which flaunting the same Zacks Rank as Corcept. You can see the complete list of today’s Zacks #1 Rank stocks here.
Avenue Therapeutics’ loss per share estimates have been narrowed 28.6% for 2020 and 26% for 2021 over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
Avenue Therapeutics, Inc. (ATXI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research